Enterprise Value
0.00
Cash
123.6M
Avg Qtr Burn
N/A
Short % of Float
4.54%
Insider Ownership
16.48%
Institutional Own.
68.39%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Milademetan (RAIN-32) w/ atezolizumab Details Solid tumor/s, Cancer | Failed Discontinued | |
Milademetan (RAIN-32) Details Solid tumor/s, Cancer | Failed Discontinued | |
Milademetan (Rain-32) Details Solid tumor/s, Cancer, Carcinoma , Metastatic merkel cell carcinoma | Failed Discontinued | |
Milademetan (Rain-32) Details Liposarcoma, Cancer, Solid tumor/s | Failed Discontinued |